Creative Medical Technology Holdings Inc (CELZ)

[NSX]

DD FOR TODAY AmnioStem: Here why TODAY’S news is great for the forward-thinking company and where it may lead:

1. AmnioStem uses “universal donor stem cells” which will be the product used for Stroke and radiation-damaged brain treatment as well as Anti-Aging.

2. July 25, 2017: CMTH released pre-clinical trials data showing that these AmnioStem (Amniotic fluid stem cells) secrete multiple active peptides including those with Immunomodulation, TNK-alpha which are tumor necrosis factors as well as Exosomes which they reported have BEEN shown to inhibit replication of Glial Brain tumors!

3. The stem cell covered by the patent (issued US Patent No. 7,569,385 ) is derived from amniotic fluid of pregnant women, which is obtained during routine amniocentesis. These cells are considered adult stem cells since no fetal damage occurs during their extraction. Amniotic fluid stem cells have been demonstrated by scientists from independent research institutions to be effective in animal models of stroke, heart attack, liver failure, colitis, diabetes, emphysema, and kidney injury.

4. These AmnioStem cells products (Exosomes, TNK) can be reproduced.

5. Exosomes are not cells, they are products! And can be mass produced and commercialized!!!

6. Exosomes are nanoparticles generated by a variety of cells that are critically involved in intercellular communication. The Company previously filed patents on the use of AmnioStem derived exosomes for treatment of stroke1 (PR 07/25/2017)

7. "From a commercialization perspective, exosomes are simpler to manufacture, store, and deliver as compared to living cells. Additionally, since exosomes are not replicating cells, we anticipate a less complicated FDA regulatory pathway as compared to cellular based products," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. (PR 07/25/2017)

8. Now, add in the “Right to Try” and you speed the process!!!! So, what is anticipated to be “a less complicated FDA regulatory pathway as compared to cellular based products” now becomes immediately available “to try” and prove efficacy and safety!!!!!

Then, CMTH should be able to get the FDA approval for “a drug” and AmnioStem as well as its products can be commercialized for clinical use---TAKING BENCHSIDE TO BEDSIDE!